|Articles|April 30, 2021

Mothers Infected With COVID-19 Pose Low Risk of Transferring Virus to Babies

Author(s)Killian Meara

While a slightly higher rate of morbidity was observed, a small percentage of babies presented with COVID-19 after birth.

A recent study conducted by investigators from the Karolinska Institutet, in collaboration with the Public Health Agency of Sweden, have discovered that mothers who have tested positive for COVID-19 pose a very low risk of passing on the virus to their newborn babies.

Results from the study were published in the journal JAMA.

The findings from the study support the recommendation from Swedish health officials that separating a newborn from their mother is not necessary.

"Separating a newborn baby from its mother is a serious intervention with negative consequences for the health of both mother and baby that must be weighed against the possible benefits," Mikael Norman, an author on the study said. "Our study suggests that mother and baby can be cared for together and that nursing can be recommended without danger to the baby's health. This is good news for all pregnant women, their babies and postnatal and neonatal staff."

For the study, the team of investigators analyzed data from nearly 90,000 births in Sweden during the first year of the COVID-19 pandemic. During this time, 2,323 babes were born to a mother who tested positive with SARS-CoV-2.

Findings from the study showed that there was a slightly higher rate of morbidity in neonates whose mothers had COVID-19, as well as an increased risk for respiratory disorders.

However, no direct correlation was observed between maternal infection and neonatal respiratory infection or pneumonia.

Additional findings showed that only 0.9% of babies born with COVID-19 infected mothers tested positive for the virus within the first 28 days of being born, and the majority who did test positive did not show any symptoms.

“Given that mothers and their infants were kept together, the results presented herein suggest that the risk of viral transmission from mothers to their newborns and older infants is low, and should it occur, infants are not severely affected,” the authors wrote. “These findings suggest that routine use of interventions such as mother-infant separation and stopping breastfeeding may not be necessary. An additional message of this study is that SARS-CoV-2 test positivity in mothers did not prolong hospital stay for families.”


Related to this article

Measles Update: October 30, 2026
The latest CDC numbers show a 5.8% increase in measles cases from week-to-week, bringing the 2026 US total to more than double the amount seen in all of 2025 with 2 months left in the year.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
FAQ: Shamonda Virus
As France confirms the first documented human Shamonda virus infection, a fatal encephalitis in a stem cell transplant recipient, this FAQ explains what the virus is, where it has spread, how the case was diagnosed, how the patient was likely infected and what clinicians should watch for.
ID Week Highlights Part 1
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.